First Time Loading...

Organon & Co
NYSE:OGN

Watchlist Manager
Organon & Co Logo
Organon & Co
NYSE:OGN
Watchlist
Price: 20.225 USD 3.72%
Updated: May 3, 2024
OGN
/
Income Statement
/
Revenue

Organon & Co
Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Organon & Co
Revenue Peer Comparison

Comparables:
JNJ
BMY
PFE
MRK
LLY

Competitive Revenue Analysis
Latest Figures & CAGR of Competitors

Company Revenue CAGR 3Y CAGR 5Y CAGR 10Y
Organon & Co
NYSE:OGN
Revenue
$6.3B
CAGR 3-Years
-1%
CAGR 5-Years
-9%
CAGR 10-Years
N/A
Johnson & Johnson
NYSE:JNJ
Revenue
$81.8B
CAGR 3-Years
-1%
CAGR 5-Years
0%
CAGR 10-Years
1%
Bristol-Myers Squibb Co
NYSE:BMY
Revenue
$45.5B
CAGR 3-Years
2%
CAGR 5-Years
14%
CAGR 10-Years
11%
Pfizer Inc
NYSE:PFE
Revenue
$58.5B
CAGR 3-Years
12%
CAGR 5-Years
7%
CAGR 10-Years
1%
Merck & Co Inc
NYSE:MRK
Revenue
$61.4B
CAGR 3-Years
14%
CAGR 5-Years
7%
CAGR 10-Years
3%
Eli Lilly and Co
NYSE:LLY
Revenue
$34.1B
CAGR 3-Years
12%
CAGR 5-Years
10%
CAGR 10-Years
4%

Organon & Co
Revenue Breakdown

Breakdown by Geography
Organon & Co

Total Revenue: 6.3B USD
100%
Int’l: 4.8B USD
76.4%
Europe And Canada: 1.7B USD
26.7%
United States: 1.5B USD
23.6%
Asia Pacific And Japan: 1.1B USD
18%
Latin America, Middle East, Russia, And Africa: 965m USD
15.4%
China: 864m USD
13.8%
Other: 154m USD
2.5%
Show More
Show Less

Breakdown by Segments
Organon & Co

Total Revenue: 6.3B USD
100%
Nexplanon/Implanon Nxt: 830m USD
13.3%
Atozet: 519m USD
8.3%
Singulair: 404m USD
6.5%
Zetia: 306m USD
4.9%
Cozaar/Hyzaar: 281m USD
4.5%
Renflexis: 278m USD
4.4%
Other Non-Opiod Pain, Bone And Dermatology: 275m USD
4.4%
Follistim Aq: 262m USD
4.2%
Arcoxia: 257m USD
4.1%
Nasonex: 253m USD
4%
Dulera: 194m USD
3.1%
Other Women's Health: 171m USD
2.7%
Fosamax: 159m USD
2.5%
Ontruzant: 155m USD
2.5%
Other Cardiovascular: 155m USD
2.5%
Nuvaring: 152m USD
2.4%
Clarinex: 136m USD
2.2%
Marvelon/Mercilon: 134m USD
2.1%
Vytorin: 129m USD
2.1%
Propecia: 125m USD
2%
Ganirelix Acetate Injection: 110m USD
1.8%
Proscar: 97m USD
1.5%
Diprospan: 91m USD
1.5%
Other Respiratory: 77m USD
1.2%
Brenzys: 73m USD
1.2%
Rosuzet: 70m USD
1.1%
Hadlima: 44m USD
0.7%
Aybintio: 43m USD
0.7%
Jada: 43m USD
0.7%
Show More
Show Less

See Also

What is Organon & Co's Revenue?
Revenue
6.3B USD

Based on the financial report for Dec 31, 2023, Organon & Co's Revenue amounts to 6.3B USD.

What is Organon & Co's Revenue growth rate?
Revenue CAGR 5Y
-9%

Over the last year, the Revenue growth was 1%. The average annual Revenue growth rates for Organon & Co have been -1% over the past three years , -9% over the past five years .

ALPHA SPREAD
Join more than 133,900+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.